LeMaitre Vascular, Inc. $LMAT Shares Acquired by Wesbanco Bank Inc.

Key Points

• Wesbanco Bank Inc. increased its stake in LeMaitre Vascular by 103.6%, owning approximately 11,400 shares valued at $947,000.
• LeMaitre Vascular's stock received upgraded ratings from analysts, with a consensus price target of $97.60 and a mix of Buy and Hold ratings.
• Insider selling was notable, with directors disposing of a total of 120,815 shares worth over $11 million in the last quarter.

Wesbanco Bank Inc. lifted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 103.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,400 shares of the medical instruments supplier's stock after acquiring an additional 5,800 shares during the quarter. Wesbanco Bank Inc. owned 0.05% of LeMaitre Vascular worth $947,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LMAT. Bank of America Corp DE increased its stake in shares of LeMaitre Vascular by 32.8% in the fourth quarter. Bank of America Corp DE now owns 61,752 shares of the medical instruments supplier's stock worth $5,690,000 after acquiring an additional 15,250 shares during the period. Cetera Investment Advisers increased its stake in shares of LeMaitre Vascular by 11.5% in the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock worth $254,000 after acquiring an additional 284 shares during the period. Deutsche Bank AG increased its stake in shares of LeMaitre Vascular by 45.2% in the fourth quarter. Deutsche Bank AG now owns 18,462 shares of the medical instruments supplier's stock worth $1,701,000 after acquiring an additional 5,747 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LeMaitre Vascular by 4.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,539 shares of the medical instruments supplier's stock worth $1,063,000 after acquiring an additional 454 shares during the period. Finally, Millennium Management LLC boosted its holdings in LeMaitre Vascular by 96.8% during the fourth quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock worth $8,853,000 after buying an additional 47,250 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LMAT. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price target on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald increased their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $97.60.

LeMaitre Vascular Trading Down 1.3%

Shares of LMAT traded down $1.17 during trading on Friday, reaching $92.25. 752,444 shares of the company traded hands, compared to its average volume of 155,007. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The stock has a market cap of $2.09 billion, a PE ratio of 44.78, a price-to-earnings-growth ratio of 2.40 and a beta of 0.79. The stock has a 50-day simple moving average of $90.52 and a 200-day simple moving average of $85.96. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same period last year, the business earned $0.52 earnings per share. The business's revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were given a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. LeMaitre Vascular's dividend payout ratio (DPR) is currently 38.83%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of LeMaitre Vascular stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $92.55, for a total transaction of $607,220.55. Following the completion of the sale, the director directly owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the sale, the director owned 2,916 shares of the company's stock, valued at approximately $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock valued at $11,280,206 in the last ninety days. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.